Advertisement

Topics

Dimerix Announces Pre-clinical Program, DMX-250, Targeting Heterodimers active in NASH, a major Liver Disease

08:13 EDT 29 Jul 2016 | Instinctif Partners

MELBOURNE, Australia, 27 July 2016: Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary assay technology, today announced a second development program, DMX-250, targeting fibrosis in patients with Non-Alcoholic Steatohepatitis (NASH).

The DMX-250 pre-clinical program is exploring the use of combinations of a series of angiotensin receptor blockers (ARB) and propagermanium (PPG), a CCR2 receptor antagonist. Dimerix has observed a positive effect with DMX-250 in the mouse model based on evaluation of industry accepted endpoints which warrants further investigation.

The ARB and PPG combinations have been selected using Dimerix’s proprietary Receptor-Heteromer Investigation Technology (Receptor-HIT). Both the Angiotensin Receptor and the Chemokine 2 Receptor are members of a group of receptors called G-Protein Coupled Receptors (GPCR’s).

NASH is part of a group of conditions called non-alcoholic fatty liver disease (NAFLD). It is a severe and increasingly recognised non-viral, progressive liver disease with an estimated 6 million suffers in the USA alone, in many cases undiagnosed. NASH carries a risk of progression to liver fibrosis and ultimately hepatocellular carcinoma. There is currently no established treatment for NASH.
Dimerix’s Executive Chairman, Dr James Williams said “Initial animal model studies have given us valuable insights into how an optimal NASH therapeutic program using our DMX-250 heterodimer approach could be developed for this common liver disease. Our early data shows signs of predicted synergies between the components of DXB-250 in the model, and further pre-clinical studies are currently being planned to confirm these observations. We are optimistic that this program has the potential to progress into human clinical trials.”

By applying the Company’s Receptor-HIT technology to receptors such as GPCRs, Dimerix is able to identify potential pharmacological effects when receptors interact as heterodimers, indicating novel and more effective routes for therapeutic intervention compared with the traditional therapeutic target development against a single receptor. The Receptor-HIT technology was used to identify the Company’s lead therapy, DMX-200, which is in a Phase II clinical trial, initially for the treatment of a subset of patients with chronic kidney disease. DMX-250 represents a second opportunity utilising the same receptor pharmacology.

At the Company Dimerix Limited James Williams Executive Chairman Tel: +61 (0) 409 050 519 E: james@dimerix.com NEXT ARTICLE

More From BioPortfolio on "Dimerix Announces Pre-clinical Program, DMX-250, Targeting Heterodimers active in NASH, a major Liver Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Assays
An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...